Comparison of calcimimetic R568 and calcitriol in mineral homeostasis in the Hyp mouse, a murine homolog of X-linked hypophosphatemia.

[1]  M. Bouxsein,et al.  1,25‐Dihydroxyvitamin D Alone Improves Skeletal Growth, Microarchitecture, and Strength in a Murine Model of XLH, Despite Enhanced FGF23 Expression , 2016, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[2]  M. Collins,et al.  1,25‐Dihydroxyvitamin D as Monotherapy for XLH: Back to the Future? , 2016, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[3]  W. Goodman,et al.  Calcimimetic and Calcilytic Drugs: Feats, Flops, and Futures , 2016, Calcified Tissue International.

[4]  D. Miao,et al.  CYP24 inhibition as a therapeutic target in FGF23-mediated renal phosphate wasting disorders. , 2016, The Journal of clinical investigation.

[5]  M. Wolf,et al.  Pruning the ricket thicket. , 2016, The Journal of clinical investigation.

[6]  G. Hendy,et al.  The calcium-sensing receptor in bone—mechanistic and therapeutic insights , 2015, Nature Reviews Endocrinology.

[7]  V. Pavone,et al.  Hypophosphatemic rickets: etiology, clinical features and treatment , 2015, European Journal of Orthopaedic Surgery & Traumatology.

[8]  P. D’Haese,et al.  Bone histomorphometry before and after long-term treatment with cinacalcet in dialysis patients with secondary hyperparathyroidism , 2014, Kidney international.

[9]  M. Baum,et al.  Regulation of renal phosphate transport by FGF23 is mediated by FGFR1 and FGFR4. , 2014, American journal of physiology. Renal physiology.

[10]  C. Wagner,et al.  The SLC34 family of sodium-dependent phosphate transporters , 2013, Pflügers Archiv - European Journal of Physiology.

[11]  S. Khundmiri,et al.  Parathyroid hormone (PTH) decreases sodium-phosphate cotransporter type IIa (NpT2a) mRNA stability. , 2013, American journal of physiology. Renal physiology.

[12]  M. Kuro-o,et al.  Fibroblast growth factor 23 and Klotho: physiology and pathophysiology of an endocrine network of mineral metabolism. , 2013, Annual review of physiology.

[13]  J. Kanis,et al.  Standardized nomenclature, symbols, and units for bone histomorphometry: A 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee , 2013, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[14]  C. Marcocci,et al.  Bone disease in primary hyperparathyrodism , 2012, Therapeutic advances in musculoskeletal disease.

[15]  B. Lanske,et al.  FGF23 acts directly on renal proximal tubules to induce phosphaturia through activation of the ERK1/2–SGK1 signaling pathway , 2012, Bone.

[16]  J. Muñoz-Castañeda,et al.  Calcium deficiency reduces circulating levels of FGF23. , 2012, Journal of the American Society of Nephrology : JASN.

[17]  H. Armbrecht,et al.  Chronic inhibition of ERK1/2 signaling improves disordered bone and mineral metabolism in hypophosphatemic (Hyp) mice. , 2012, Endocrinology.

[18]  Martin Y. H. Zhang,et al.  Fibroblast growth factor 23 regulates renal 1,25‐dihydroxyvitamin D and phosphate metabolism via the MAP kinase signaling pathway in Hyp mice , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[19]  I. Holm,et al.  A clinician's guide to X‐linked hypophosphatemia , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[20]  D. Haffner,et al.  Age-related stature and linear body segments in children with X-linked hypophosphatemic rickets , 2011, Pediatric Nephrology.

[21]  D. Goltzman,et al.  Comparison of active vitamin D compounds and a calcimimetic in mineral homeostasis. , 2010, Journal of the American Society of Nephrology : JASN.

[22]  E. Farrow,et al.  Altered renal FGF23-mediated activity involving MAPK and Wnt: effects of the Hyp mutation. , 2010, Journal of Endocrinology.

[23]  Ralph Müller,et al.  Guidelines for assessment of bone microstructure in rodents using micro–computed tomography , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[24]  L. Dimeglio,et al.  Treatment of X-linked hypophosphatemia with calcitriol and phosphate increases circulating fibroblast growth factor 23 concentrations. , 2010, The Journal of clinical endocrinology and metabolism.

[25]  M. Razzaque,et al.  Isolated C-terminal tail of FGF23 alleviates hypophosphatemia by inhibiting FGF23-FGFR-Klotho complex formation , 2009, Proceedings of the National Academy of Sciences.

[26]  E. Farrow,et al.  Initial FGF23-mediated signaling occurs in the distal convoluted tubule. , 2009, Journal of the American Society of Nephrology : JASN.

[27]  Jason R. Stubbs,et al.  Calcimimetics as an adjuvant treatment for familial hypophosphatemic rickets. , 2008, Clinical journal of the American Society of Nephrology : CJASN.

[28]  A. Arnold,et al.  Parathyroid hormone regulates fibroblast growth factor-23 in a mouse model of primary hyperparathyroidism. , 2007, Journal of the American Society of Nephrology : JASN.

[29]  D. Miao,et al.  Early lethality in Hyp mice with targeted deletion of Pth gene. , 2007, Endocrinology.

[30]  R. Jilka.  Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. , 2007, Bone.

[31]  Jason R. Stubbs,et al.  Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. , 2006, Journal of the American Society of Nephrology : JASN.

[32]  M. Haussler,et al.  1alpha,25-Dihydroxyvitamin D3 upregulates FGF23 gene expression in bone: the final link in a renal-gastrointestinal-skeletal axis that controls phosphate transport. , 2005, American journal of physiology. Gastrointestinal and liver physiology.

[33]  R. L. Cain,et al.  Anabolic and catabolic bone effects of human parathyroid hormone (1-34) are predicted by duration of hormone exposure. , 2003, Bone.

[34]  O. Mäkitie,et al.  Early treatment improves growth and biochemical and radiographic outcome in X-linked hypophosphatemic rickets. , 2003, The Journal of clinical endocrinology and metabolism.

[35]  K. White,et al.  Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. , 2003, The New England journal of medicine.

[36]  Y. Takeuchi,et al.  Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. , 2002, The Journal of clinical endocrinology and metabolism.

[37]  J. Reginster,et al.  Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. , 2001, The New England journal of medicine.

[38]  M. Pfaffl,et al.  A new mathematical model for relative quantification in real-time RT-PCR. , 2001, Nucleic acids research.

[39]  S. Roy,et al.  Increased renal 25-hydroxyvitamin D3-24-hydroxylase messenger ribonucleic acid and immunoreactive protein in phosphate-deprived Hyp mice: a mechanism for accelerated 1,25-dihydroxyvitamin D3 catabolism in X-linked hypophosphatemic rickets. , 1994, Endocrinology.

[40]  J. Simpson,et al.  Effects of therapy in X-linked hypophosphatemic rickets. , 1991, The New England journal of medicine.

[41]  M. Kleerekoper,et al.  Relationships between surface, volume, and thickness of iliac trabecular bone in aging and in osteoporosis. Implications for the microanatomic and cellular mechanisms of bone loss. , 1983, The Journal of clinical investigation.

[42]  D. Shoback,et al.  Interplay between CaSR and PTH1R signaling in skeletal development and osteoanabolism. , 2016, Seminars in cell & developmental biology.

[43]  K. Mahaffey,et al.  Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial Heart Failure , 2015 .

[44]  J. Wetmore,et al.  Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD. , 2010, Clinical journal of the American Society of Nephrology : CJASN.